Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®

Laurent Magnenat, Angelo Palmese, Christèle Fremaux, Fabio D’Amici, Mariagrazia Terlizzese, Mara Rossi, \[4\] and Laurent Chevalet

\[^{a}\]Non clinical Pharmacology, Merck Biosimilars, Aubonne, Switzerland; \[^{b}\]Department of Protein Chemistry, Merck, Guidonia Montecelio – Rome, Italy; \[^{c}\]Non clinical Pharmacology, Merck Biosimilars, Corsier-sur-Vevey, Switzerland; \[^{d}\]Bioanalytical Development, Pharmaceutical & Analytical Development Biotech Products, Merck, Guidonia Montecelio – Rome, Italy; \[^{e}\]Analytical and Pharmaceutical Development, Merck Biosimilars, Aubonne, Switzerland

ABSTRACT

Biosimilars are biological products that are highly similar to existing products approved by health authorities. Demonstration of similarity starts with the comprehensive analysis of the reference product and its proposed biosimilar at the physicochemical and functional levels. Here, we report the results of a comparative analysis of a proposed biosimilar adalimumab MSB11022 and its reference product, Humira®. Three batches of MSB11022 and up to 23 batches of Humira® were analyzed by a set of state-of-the-art orthogonal methods. Primary and higher order structure analysis included N/C-terminal modifications, molecular weight of heavy and light chains, C-terminal lysine truncation, disulfide bridges, secondary and tertiary structures, and thermal stability. Purity ranged from 98.4%–98.8% for MSB11022 batches (N = 3) and from 98.4%–99.6% for Humira® batches (N = 19). Isoform analysis showed 5 isoform clusters within the pl range of 7.94–9.14 and 100% glycan site occupancy for both MSB11022 and Humira®. Functional analysis included Fab-dependent inhibition of tumor necrosis factor (TNF)-induced cytotoxicity in L929-A9 cell line and affinity to soluble and transmembrane forms of TNF, as well as Fc-dependent binding to Fcγ and neonatal Fc receptors and C1q complement proteins. All tested physicochemical and functional parameters demonstrated high similarity of MSB11022 and Humira® with lower variability between MSB11022 and Humira® batches compared with variability within individual batches of Humira®. Based on these results, MSB11022 is anticipated to have safety and efficacy comparable to those of Humira®.

Abbreviations: 4PL, 4-parameter logistic; Asn, asparagine; AUC, analytical ultracentrifugation; CD, circular dichroism; C\textsubscript{max}, maximum observed concentration; DTT, dithiothreitol; EC\textsubscript{50}, half-maximal effective concentration; ELISA, enzyme-linked immunosorbent assay; EMA, European Medicines Agency; Fab, fragment antigen-binding; FC, fragment crystallizable; FDA, US Food and Drug Administration; Gln, glutamine; HC, heavy chain; HMW, high-molecular weight; idEF, imaged capillary isoelectric focusing; LC, light chain; Lys, lysine; mAbs, monoclonal antibodies; Met, methionine; MS, mass spectrometry; MW, molecular weight; pI, isoelectric point; PK, pharmacokinetic; Pro, proline; Q-TOF, quadrupole time of flight; SDS, sodium dodecyl sulfate; SEC, size-exclusion chromatography; SPR, surface plasmon resonance; TM, thermal transitions; TNF, tumor necrosis factor; Tris, Tris(hydroxymethyl)aminomethane; UPLC-MS/MS, ultra-performance liquid chromatography-tandem mass spectrometry; UV, ultraviolet; VH, variable domain of the heavy chain; VL, variable domain of the light chain

Introduction

Biological products, or biologics, such as growth factors and antibodies are medical products derived from natural sources or produced recombinantly in cells.\(^1\) Biologics are widely used for the treatment, prophylaxis and diagnosis of diseases. The expiration of patents for biological products enables the development of so-called biosimilars, which are biologics approved by regulatory agencies (based on very stringent guidelines), and are highly similar to their reference products.\(^2,3\)

Biosimilar development aims to provide high-quality biological treatment to a broader patient population by increasing consumer access to drugs that are more affordable than the original product.\(^4,5\) The increased use of monoclonal antibody (mAb) therapies represents a major cost burden for healthcare providers. The high cost of treatment with originator biologics limits access, leading to an unmet medical need in the US and other parts of the world.\(^5\) The development of biosimilars can have a critical effect on the affordability and access to biologics in all markets, allowing more patients to be treated. For example, the cost savings upon the introduction of biosimilar infliximab for the treatment of autoimmune diseases in 5 EU countries would enable up to an additional 7561 patients to be treated (with 10–30% discount scenarios projecting €26–77 million in savings).\(^6\)
The development of biosimilars is guided by scientifically rigorous principles mandated by regulatory agencies in the EU, the US, and other highly regulated regions of the world. Much greater analytical scrutiny and in-depth functional characterization are required for the approval of a biosimilar compared with the characterization performed for the approval of the original drug, as these are the foundations for comparable safety and efficacy performance in the clinic. The use of state-of-the-art orthogonal analytical technologies for the characterization of biosimilars, which are typically more extensive and diverse than those used during the development of the original product, are important in establishing confidence in biosimilars. Owing to their quality-driven development, currently marketed biosimilars that have been available in the EU for several years demonstrate similar efficacy and safety profiles compared with their reference products.

Adalimumab (Humira®, AbbVie Inc.) is a recombinant human monoclonal immunoglobulin G1 (IgG1) that binds specifically to tumor necrosis factor (TNF) and blocks its general cytokine effects by preventing the interaction with p55 and p75 cell surface TNF receptors. As a consequence, adalimumab modulates TNF-mediated cellular functions.

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved adalimumab for the treatment of the following immune system-mediated diseases: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, adult and pediatric Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and uveitis.

We report here the physicochemical and functional comparability of a proposed adalimumab biosimilar (MSB11022, Merck) and Humira®. We compared 3 MSB11022 batches (AL1D001–AL1D003) generated from independent drug substance produced at large scale with 13–23 batches of Humira® sourced from 2 regions (US and EU). A large panel of methods using orthogonal approaches was applied, as shown in Table 1. This allowed in-depth characterization at the physicochemical and functional level of MSB11022 in comparison to Humira®. The data presented here demonstrate that the manufacturing process of MSB11022 generates a high-quality product that is well aligned with the variability observed in Humira®.

**Results**

**Primary structure and posttranslational modifications**

Amino acid sequences for MSB11022 and Humira® were determined by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS and UV [UV] absorbance). The tryptic peptide maps were identical among 3 batches of MSB11022 and 21 batches of Humira®, without missing peaks or shifts in retention time (representative data shown in Fig. 1). The peptide mapping analysis confirmed that the primary structure was identical with 100% of sequence coverage (data not shown).

Peptide mapping by UPLC-MS/MS also enabled the assessment of N- and C-terminal heterogeneity. The N-/C-terminal sequence of the light chain (LC) was confirmed to be identical between MSB11022 and Humira®, without any missing amino acids in the primary structure. For the heavy chain (HC), minor heterogeneities between MSB11022 and Humira® were found. The N-/C-terminal modifications (pyro-glutamic acid (Glu), lysine (Lys) truncation, C-terminal proline (Pro) amidation) of MSB11022 were less variable among the batches and fell within the respective ranges observed for Humira® (Table 2). Overall, N-/C-terminal modifications were shown to be similar among the 3 batches of MSB11022 and 21 batches of Humira® (Table 2).

Oxidation/deamidation sites and levels were also determined by peptide mapping by UPLC-MS/MS. The levels of oxidized methionine (Met) for all 5 major oxidation sites were less variable among the batches of MSB11022 (N = 3) and fell within the respective ranges observed for Humira® (N = 21; Table 2). Met252 was the most oxidized HC Met in all tested samples. The highest levels of Met252 oxidation were 10-fold higher in Humira® batches compared with those in MSB11022 batches. Overall, lower oxidation levels were seen in MSB11022 compared with Humira®. Similarly, deamidation and succinimidation of asparagine (Asn) and glutamine (Gln) residues were less variable among the batches of MSB11022 (N = 3) and fell within the respective ranges observed for Humira® (N = 21, data not shown).

The expected molecular weight (MW) of the LC and HC was in agreement with the theoretical MWs and similar for all batches Humira® and MSB11022 by whole-domain liquid chromatography-mass spectrometry (LC-MS; data not shown). Potential micro-heterogeneity was also evaluated. The possibility of incorporation of serine into Asn positions in Chinese hamster ovary cells was reported; such misincorporated species were not observed in any of the tested MSB11022 and Humira® batches (data not shown).

The relative distribution of the intact and glycated forms of both LC and HC, as well as C-terminal Lys truncation of HC level of MBS11022, fell within the respective ranges of Humira® batches (Table 2). All batches showed as main species the intact LC and the HC processed at its C-terminus (Lys removal).

**High-order structure**

When we assessed disulfide bridges by peptide mapping UPLC-MS/MS, all 9 expected disulfide bridges were identified in non-reducing condition and the expected configuration was confirmed in all tested samples (3 batches of MSB11022 and 21 batches of Humira®; representative data shown in Fig. 2).

Thermal stability was determined by Nano DSC. All the tested batches presented 3 thermal transitions (Tm) with similar transition temperatures (Table 2). These findings were consistent with the 3 Tms reported for humanized monoclonal IgG1 in the literature. Tm1 and Tm2 are attributable to the denaturation of the constant CH2 and the antigen-binding fragment (Fab) domains, respectively, and Tm3 to the denaturation of the constant CH3 domain, as described by Garber et al.

No differences in the secondary (α-helix, β-sheet, turn) and tertiary structures (folding properties) were observed between Humira® and MSB11022 batches by circular dichroism (CD) measuring both far-UV and near-UV CD spectra (Fig. 3).

**Purity and impurities**

The purity of MSB11022 and Humira® was evaluated by Bioanalyzer. Similar purity levels and low–molecular-weight (LMW)
species were found for MSB11022 and Humira®. In both reducing and non-reducing conditions, purity ranges were similar between MSB11022 and Humira® batches. Minor impurity peaks were detectable between lower and upper MW markers, and the sum of these peaks accounted for less than 1.7% of the integrated areas in the non-reducing conditions (Fig. 4).

Similar aggregates/high–molecular-weight (HMW) species levels and monomer purity were observed in MSB11022 and Humira® batches by size-exclusion chromatography (SEC; Table 2).

These results were confirmed by an orthogonal approach, analytical ultracentrifugation (AUC), showing comparable proportions of monomer, aggregates/HMW, dimers and fragments between MSB11022 and Humira® (Table 2). With three different methods, comparable purity and impurity levels were demonstrated for MSB11022 and Humira®.

Table 1. Physicochemical and Functional Quality Attributes.

| Attribute                                      | Analytical Technique                             | Aim of the test                      |
|------------------------------------------------|-------------------------------------------------|--------------------------------------|
| Primary structure and posttranslational modifications | Peptide mapping by UPLC-MS/MS                     | Primary structure confirmation and coverage Deamidation/oxidation N/C-terminal modifications |
|                                                 | Whole-molecule analysis by LC-MS                 | Intact LC and HC Glycation level Misincorporation |
| High-order structure                           | Circular dichroism                               | Secondary and tertiary structures NaN DSC                                          |
|                                                 | Peptide mapping by UPLC-MS/MS                   | Thermal stability (identification of thermal transitions) Assessment of disulfide bridges |
| Purity and impurities                          | Purity by Bioanalyzer                            | Evaluation of purity Aggregation, purity levels Monomer purity and HMW |
|                                                 | Aggregation by SEC                               | Isomorph distribution Isoform values |
| Product variants                               | Charge variants by icIEF                          | Glycan site occupancy Inhibition of TNF-induced L929-A9 cytotoxicity Affinity to TNF |
| Fab binding and potency                        | Peptide mapping by UPLC-MS/MS                   | Affinity to Fcγ-R1 Affinity to Fcγ-Rlla R131 & H131 |
|                                                 | In vitro bioassay (rel. pot. [%EC50])             | Affinity to Fcγ-Rllb Affinity to Fcγ-Rlla V158 & F158 |
|                                                 | SPR (affinity [Kd])                              | Affinity to Fcγ-Rllb Affinity to neonatal FcR |
| Fc binding                                     | FACS (relative binding [%EC50])                  | ELISA (rel. binding [%EC50]) Binding to Clq |
|                                               | SPR (affinity [Kd])                              |                                      |

*Method fully validated in line with ICH Q2(R1) guidelines (ICH Guidelines).28

AUC, analytical ultracentrifugation; ELISA, enzyme-linked immunosorbent assay; HC, heavy chain; HMW, high-molecular weight; icIEF, imaged capillary isoelectric focusing; LC, light chain; LC-MS, liquid chromatography-mass spectrometry; SEC, size-exclusion chromatography; SPR, surface plasmon resonance; tm-TNF, transmembrane TNF; TNF, tumor necrosis factor; UPLC-MS/MS, ultra-performance liquid chromatography-tandem mass spectrometry.

![Figure 1](image1.png)

**Figure 1.** Comparison of total UPLC peptide mapping profiles between MSB11022 and Humira®. Representative UPLC peptide mapping profiles (total ion chromatograms) are presented for 3 batches of MSB11022 (AL1D001, AL1D002, and AL1D003) and 2 Humira® batches (1017235 and 37461XD07).
Table 2. Primary Structure, High-Order Structure, and Purity Quality Attribute Ranges of MSB11022 and Humira®.

| Quality Attributes                          | Products       | N     | Min/Max Ranges (EU, US) | Mean (SD) | Bar Diagrams (normalized scale) |
|--------------------------------------------|----------------|-------|-------------------------|-----------|-------------------------------|
| Primary Structure, High-Order Structure    |                |       |                         |           |                               |
| N-terminus Heterogeneity by Peptide Mapping | MSB11022       | 3     | 1.8–2.1                 | 1.9 (0.2) |                               |
|                                            | Humira®        | 21    | 1.0–2.2 (1.2–2.2, 1.0–1.9) | 1.6 (0.3) |                               |
|                                            |                |       |                         |           |                               |
| Truncation and Glycation Levels by Whole Domain LCMS (%) |                |       |                         |           |                               |
| Intact LC                                  | MSB11022       | 3     | 97.7–97.7               | 97.7 (0.6) |                               |
|                                            | Humira®        | 16    | 96.8–98.3 (96.8–98.3, 96.9–98.2) | 97.6 (0.4) |                               |
| Glycated LC                                | MSB11022       | 3     | 2.3–3.2                 | 2.3 (0.0) |                               |
|                                            | Humira®        | 16    | 1.3–3.2 (1.3–3.2, 1.8–3.1) | 2.2 (0.5) |                               |
| Truncated HC Delta (C-term Gly-Lys)         | MSB11022       | 3     | <LOD                    | 0.0       |                               |
|                                            | Humira®        | 16    | <LOD–4.6 (<LOD–3.5, <LOD–4.6) | 1.6 (2.0) |                               |
| Truncated HC Delta (C-term Gly-Lys)         | MSB11022       | 3     | 77.2–78.8               | 77.7 (0.9) |                               |
|                                            | Humira®        | 16    | 74.1–80.3 (73.7–80.3, 74.1–80.2) | 77.9 (2.6) |                               |
| Intact HC                                  | MSB11022       | 3     | 14.4–15.3               | 14.9 (0.5) |                               |
|                                            | Humira®        | 16    | 13.1–16.5 (13.1–14.8, 13.3–15.5) | 14.5 (1.6) |                               |
| Glycated HC                                | MSB11022       | 3     | 8.8–7.8                 | 7.4 (0.5) |                               |
|                                            | Humira®        | 16    | 4.4–7.9 (4.4–7.9, 4.7–7.3) | 6.0 (1.3) |                               |
| Nano DSC (°C)                              | MSB11022       | 3     | 72.98–73.90             | 73.0 (0.6) |                               |
|                                            | Humira®        | 19    | 72.49–73.90 (73.00–73.87, 72.49–73.99) | 73.6 (0.4) |                               |
|                                            |                |       |                         |           |                               |
| Purity and impurities (HMW and LMW) under non-reducing (NR) and reducing conditions (R) by Bioanalyzer (%) |                |       |                         |           |                               |
| Purity (NR)                                | MSB11022       | 3     | 98.4–98.8               | 98.4 (0.2) |                               |
|                                            | Humira®        | 19    | 98.4–98.9 (98.4–98.6, 98.4–98.9) | 99.0 (0.5) |                               |
| Purity (R)                                 | MSB11022       | 3     | 98.4–98.8               | 97.4 (0.8) |                               |
|                                            | Humira®        | 19    | 98.4–98.9 (98.4–98.7, 98.8–98.8) | 97.3 (0.4) |                               |
| Aggregates/HMW Species, Purity and LMW Species by SEC (%) |                |       |                         |           |                               |
| Aggregates/HMW                             | MSB11022       | 3     | 0.3–0.4                 | 0.4 (0.0) |                               |
|                                            | Humira®        | 20    | 0.2–0.5 (0.3–0.5, 0.2–0.4) | 0.3 (0.1) |                               |
| Purity                                     | MSB11022       | 3     | 99.5–99.6               | 99.6 (0.0) |                               |
|                                            | Humira®        | 20    | 98.5–99.6 (98.5–99.5, 98.2–99.9) | 99.3 (0.3) |                               |
| LMW Species                                | MSB11022       | 3     | 0.1–0.1                 | 0.1 (0.0) |                               |
|                                            | Humira®        | 20    | 0.1–1.0 (0.1–1.0, 0.1–0.5) | 0.3 (0.2) |                               |
| Aggregates/HMW Species, Monomer, Dimer & Fragments by AUC (%) |                |       |                         |           |                               |
| Aggregates/HMW                             | MSB11022       | 3     | 0.1–0.9                 | 0.4 (0.4) |                               |
|                                            | Humira®        | 17    | <LOD–3.3 (<LOD–2.8, <LOD–3.3) | 1.0 (1.0) |                               |
| Purity                                     | MSB11022       | 3     | 97.9–98.7               | 97.8 (0.9) |                               |
|                                            | Humira®        | 17    | 92.7–99.4 (93.6–97.5, 92.7–99.4) | 96.9 (1.8) |                               |
| Dimer                                      | MSB11022       | 3     | 0.5–1.7                 | 1.2 (0.6) |                               |
|                                            | Humira®        | 17    | 0.2–3.1 (0.6–3.1, 0.2–2.5) | 1.5 (0.9) |                               |
| Fragments                                  | MSB11022       | 3     | 0.4–0.8                 | 0.6 (0.2) |                               |
|                                            | Humira®        | 17    | <LOD–1.7 (<LOD–1.2, <LOD–1.5) | 0.8 (0.5) |                               |
| Oxidation Levels by Peptide Mapping MS (%) | MSB11022       | 3     | 0.3–0.3                 | 0.3 (0.0) |                               |
|                                            | Humira®        | 21    | <LOD–1.5 (<LOD–1.5, 0.2–1.4) | 0.7 (0.5) |                               |
| Met (30) VH                                | MSB11022       | 3     | 0.1–0.1                 | 0.1 (0.0) |                               |
|                                            | Humira®        | 21    | <LOD–1.1 (<LOD–1.1, 0.1–0.9) | 0.4 (0.3) |                               |
| Met (91) VH                                | MSB11022       | 3     | 0.9–1.1                 | 0.1 (0.1) |                               |
|                                            | Humira®        | 21    | <LOD–10.5 (<LOD–5.0, 1.1–10.5) | 3.0 (2.8) |                               |
| Met (252) HC                               | MSB11022       | 3     | 0.3–0.4                 | 0.4 (0.1) |                               |
|                                            | Humira®        | 21    | 0.1–2.1 (0.1–0.5, 0.2–2.1) | 0.8 (0.5) |                               |
| Met (428) HC                               | MSB11022       | 3     | 0.3–0.4                 | 0.3 (0.1) |                               |
|                                            | Humira®        | 21    | <LOD–2.2 (<LOD–0.8, <LOD–2.2) | 0.5 (0.5) |                               |
| Total Oxidation                            | MSB11022       | 3     | 1.9–2.3                 | 2.1 (0.2) |                               |
|                                            | Humira®        | 21    | 1.5–15.7 (1.5–8.6, 2.0–15.7) | 5.1 (4.0) |                               |

Abbreviations: AUC = analytical ultracentrifugation; HC = heavy chain; HMW = high molecular weight; LCMS = liquid chromatography-tandem mass spectrometry; LMW = low molecular weight; <LOD = below limit of detection; MS = mass spectrometry; N = number; NR = non-reducing; R = reducing; SEC = size exclusion chromatography; SD = standard deviation; TM = thermal transition; VH = variable domain of the heavy chain; VL = variable domain of the light chain. The limit of detection (LOD) of the oxidation level determination is 0.05%. 1US and EU batches of Humira®. 2Bar diagrams represent MSB11022 max range normalized to Humira® min/max range for each quality attribute. 3Labelled according to ImmunoGenetics (IMGT) numbering. 4Labelled according to EU numbering.
dissociation constant ($K_D$), was found among 13 Humira® batches and 3 MSB11022 batches (Table 4).

Binding to transmembrane TNF (tm-TNF) by flow cytometry was shown to be highly similar, as expressed by the half-maximal effective concentration (EC$_{50}$), among the 22 Humira® batches and the 3 MSB11022 batches (Table 4).

Fragment crystallizable (Fc) binding

Highly similar Fc binding properties were found among both Humira® and MSB11022 batches, as measured by affinity to various Fcγ extracellular domains (RI, RIIa R131 & H131, RIIb, RIIa V158 & F158, RIIb), and by relative binding to C1q (Table 4). Kinetic binding sensorgrams were not distinguishable between MSB11022 and RP/RMP, as illustrated for the binding to the high-affinity allotype, FcyRIIa V158 and to the low-affinity allotype, FcyRIIa F158. While the affinity range of MSB11022 for binding to FcyRIIa V158 is within the range of Humira®, overlapping binding patterns for binding to FcyRIIa F158 were observed for MSB11022 and Humira®. Considering method variability using SPR, MSB11022 (3 batches with a mean affinity of 8 nM and a standard deviation of 0.9 nM) and Humira® (23 batches with a mean affinity of 6.9 nM and a standard deviation of 0.6 nM) are therefore also considered highly similar for binding to FcyRIIa F158 (Table 4, Fig. 6).

Degradation under stress conditions

Accelerated and stress stability studies are expected to be part of the demonstration of similarity to establish degradation profiles and provide direct comparison of the proposed biosimilar product with the reference product. Therefore, the comparative analysis of MSB1022 and Humira® was complemented by a pilot forced degradation study. A range of stress conditions were applied to MSB11022 and Humira® in a head-to-head setting. These conditions, comprising thermal stress, oxidation, deamidation, acidic pH stress, and mechanical stress, were chosen to

| Peak | Chain | Disulfide bridges |
|------|-------|-------------------|
| A    | HC- HC intra chain | C261 – C321'h |
| B    | HC- HC intra chain | C367 – C425'h |
| C    | HC- HC intra chain | C23 – C104'|
| D    | LC- LC intra chain | C134 – C194'|
| E    | LC- LC intra chain | C23 – C104'|
| F    | LC- HC inter chain | C214 – C220'|
| G    | HC- HC inter chain (hinge region) | C226 – C226' |
| H    | HC- HC intra chain | C229 – C229'|

*Labelled according to EU numbering. *Labelled according to ImmunoGenetics (IMGT) numbering.
generate different degradation pathways, and to provide an orthogonal assessment of degradation trends. No substantial differences were noted between MSB11022 and Humira® behavior upon various stress treatments (data not shown).

**Discussion**

Structural elements of a protein are critical determinants for its function; therefore, biosimilar development depends on extensive structural and functional characterization.

Requirements for the level of comparability between biosimilar mAbs and their reference products are as strict as, yet more comprehensive, than those for small molecules and less-complex biologics. State-of-the-art analytical methodologies measuring physicochemical and biological properties are applied to compare biosimilars with their reference products with a high level of scrutiny. Analytical programs should have at least 3 levels of testing: 1) release testing (and routine in-process testing) providing information on product attributes; 2) extended physico-chemical and biological characterization that comprehensively characterizes the biochemistry of a product; and 3) stability studies analyzing any changes over time. Variability of product characteristics is intrinsic to complex living cell production processes, and acceptable changes in quality attributes have been described. The quality range of an originator drug becomes more broad with changes in the production process, and this whole range could be used for claiming biosimilarity; however, biosimilars’ sponsors, in collaboration with health authorities, typically select tighter quality ranges for their products.

In this study, we investigated the physicochemical and functional comparability of a proposed adalimumab biosimilar (MSB11022) and Humira®. The manufacturing process was designed to achieve a quality that is similar to Humira®. In the early phase of experiments (data not shown), MSB11022 was selected based on rigorous testing.

![Figure 3. High-order structure analysis by CD. Representative near-UV CD spectrum (A) and far-UV CD spectrum (B) of MSB11022 and Humira® suggesting similar of tertiary and secondary structures, respectively.](image-url)
for analytical similarity to Humira\(^\text{®}\). Cell line selection and the process development activities were performed in a stepwise manner using the principles of quality by design, and were guided by the target ranges of the quality attributes of multiple batches of Humira\(^\text{®}\). Multiple cell lines and hundreds of upstream and downstream process iterations were tested on a small scale with varying process parameters. The resulting materials from these multiple process versions were tested for analytical similarity to Humira\(^\text{®}\) to support the selection of the final cell line and upstream/downstream process. The selected process was subsequently scaled up to 5000 L for the production of MSB11022. In the current work, MSB11022 was submitted to a comprehensive comparison to Humira\(^\text{®}\) with a panel of methods.

The primary structure and high-order structure of MSB11022 and Humira\(^\text{®}\) were thoroughly compared using orthogonal methods. The peptide mapping mass spectrometry (MS) and whole-molecule MS results demonstrated across a large number of batches that the primary structure of MSB11022 and Humira\(^\text{®}\) was identical (data not shown), N-/C-terminal heterogeneity and posttranslational modification patterns were similar, and disulfide bridge pattern was identical. The oxidation level in MSB11022 batches fell within the range observed for Humira\(^\text{®}\) (Table 2).

The Nano DSC results demonstrated MSB11022 and Humira\(^\text{®}\) have similar thermal unfolding patterns, and these combined with the CD results suggest that MSB11022 and Humira\(^\text{®}\) have similar secondary and tertiary structures (Fig. 3).

Three bioanalytical methods (Bioanalyzer, SEC, and AUC) demonstrated similar monomer purity levels, LMW species, and aggregation states for MSB11022 and Humira\(^\text{®}\) (Table 2, Fig. 4). A comparable charge variants profile between the 2 products was observed by icIEF (Table 3). Taken together, the set of orthogonal approaches demonstrated that the primary, secondary, and tertiary structures, purity, aggregation states, and charge profile of MSB11022 and Humira\(^\text{®}\) were similar. Functional comparability assays (cell-based bioassay, SPR, flow cytometry, and enzyme-linked immunosorbent assay [ELISA]) demonstrated highly similar relative potency for Fab-dependent inhibition of the TNF cytotoxic effect between MSB11022 and Humira\(^\text{®}\), as well as highly similar affinity for binding to soluble TNF, cellular tm-TNF, various Fc\(\gamma\) receptor extracellular domains, and C1q (Table 4).

Moreover, highly similar affinity of binding was also observed for MSB11022 and Humira\(^\text{®}\) toward the neonatal FcR (Table 4). Binding to FcRn by SPR has been shown to be sensitive to oxidation levels in the Fc portion of IgG\(\text{1}\),\(^\text{17,18}\) and high-affinity binding to this receptor is known to increase the serum elimination half-life of mAbs.\(^\text{19,20}\) This comparable binding affinity is expected to be indicative of similar pharmacokinetic (PK) profiles of MSB11022 and Humira\(^\text{®}\), and recently published data confirm this.\(^\text{21}\) Data from a phase 1 study comparing the PK profiles of MSB11022 and Humira\(^\text{®}\) show PK equivalence for MSB11022 for all primary endpoints (area

| Table 3. Charge Variants by icIEF of MSB11022 and Humira\(^\text{®}\). |
|---------------------------------------------|
| N                  | Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | Cluster 5 |
|---------------------|-----------|-----------|-----------|-----------|-----------|
|                     | pl 7.94–8.42 | pl 8.49–8.67 | pl 8.65–8.80 | pl 8.80–8.95 | pl 8.94–9.14 |
| MSB11022            | 3         | 6.9–8.8   | 12.1–12.6 | 55.8–56.9 | 18.8–19.4 | 4.1–4.6 |
| Humira\(^\text{®}\) EU | 10        | 6.3–10.5  | 11.6–13.5 | 54.7–61.4 | 15.6–20.1 | 3.4–5.4 |
| Humira\(^\text{®}\) US | 11        | 6.5–8.9   | 10.9–13.2 | 54.9–59.7 | 16.6–20.0 | 4.3–5.5 |

icIEF, imaged capillary isoelectric focusing.
under the curve, maximum observed concentration \([C_{\text{max}}]\), and area under curve from time 0 to the last quantifiable concentration. Therefore, these results confirmed that both drugs have highly similar structural determinants and functional properties.

Analytical similarity assessment is ongoing, including the characterization of structure-function relationships, investigation of other quality attributes and orthogonal assessment of the current analytical panel via additional analytic methods, side-by-side analysis of the degradation profile/kinetics of Humira\(^a\) and MSB11022 in stress conditions, characterization of product impurities/variants, and nonclinical pharmacodynamic studies aimed at probing mechanisms of action. It is anticipated that the data generated during these investigations will support the conclusion that MSB11022 is analytically similar to Humira\(^a\).

Table 4. Fab Binding and Fc Binding Quality Attribute Ranges of MSB11022 and Humira\(^a\).

| Fab Binding and Potency Assay Ranges | Products | N | Min/Max Ranges (EU, US)\(^a\) | Mean (SD) | Bar Diagrams (normalized scale)\(^a\) |
|-------------------------------------|----------|---|-------------------------------|-----------|------------------------------------|
| EC\(_{50}\) (%)                      | MSB11022 | 3 | 89–100                        | 99.3 (0.6) | 0.2 0.4 0.6 0.8 1 1.2             |
|                                    | Humira\(^a\) | 19 | 86–106 (86–99, 86–106)        | 92.8 (6.0) | 0.2 0.4 0.6 0.8 1 1.2             |
| **Affinity to Soluble TNF\(_{\alpha}\) by SPR** | | | | | |
| \(K_d\) (pM)                        | MSB11022 | 3 | 100–116                       | 110.0 (5.3) | 0.2 0.4 0.6 0.8 1 1.2             |
|                                    | Humira\(^a\) | 13 | 93–149 (93–149, 103–128)      | 112.8 (14.8) | 0.2 0.4 0.6 0.8 1 1.2             |
| **Binding to tm-TNF\(_{\alpha}\) by Flow Cytometry** | | | | | |
| EC\(_{50}\) (%)                      | MSB11022 | 3 | 87–93                         | 90.3 (3.3) | 0.2 0.4 0.6 0.8 1 1.2             |
|                                    | Humira\(^a\) | 22 | 79–102 (79–102, 82–102)      | 92.8 (7.3) | 0.2 0.4 0.6 0.8 1 1.2             |

| Fc Binding Assay Ranges | Products | N | Min/Max Ranges (EU, US)\(^a\) | Mean (SD) | Bar Diagrams (normalized scale)\(^a\) |
|------------------------|----------|---|-------------------------------|-----------|------------------------------------|
| Affinity to FcyRII by SPR | | | | | |
| \(K_d\) (nM)           | MSB11022 | 3 | 18–21                         | 19.2 (2.0) | 0.2 0.4 0.6 0.8 1 1.2             |
|                       | Humira\(^a\) | 16 | 15–23 (18–23, 15–21)        | 19.5 (2.5) | 0.2 0.4 0.6 0.8 1 1.2             |
| **Affinity to FcyRIIa R131 & H131 by SPR** | | | | | |
| \(K_d\) (nM) (R131)  | MSB11022 | 3 | 4.8–11.9                      | 7.9 (3.7)  | 0.2 0.4 0.6 0.8 1 1.2             |
|                      | Humira\(^a\) | 22 | 3.2–13.0 (4.2–13.0, 3.2–10.5) | 8.0 (2.4)  | 0.2 0.4 0.6 0.8 1 1.2             |
| \(K_d\) (nM) (H131) | MSB11022 | 3 | 5.0–6.2                       | 5.8 (0.6)  | 0.2 0.4 0.6 0.8 1 1.2             |
|                      | Humira\(^a\) | 22 | 4.3–10.7 (4.3–10.7, 5.2–9.8) | 6.8 (1.6)  | 0.2 0.4 0.6 0.8 1 1.2             |
| **Affinity to FcyRIIb by SPR** | | | | | |
| \(K_d\) (nM)           | MSB11022 | 3 | 8.2–10.5                      | 9.3 (1.2)  | 0.2 0.4 0.6 0.8 1 1.2             |
|                       | Humira\(^a\) | 21 | 4.3–14.2 (6.7–14.2, 4.3–12.2) | 8.7 (2.3)  | 0.2 0.4 0.6 0.8 1 1.2             |
| **Affinity to FcyRIIa V158 & F158 by SPR** | | | | | |
| \(K_d\) (nM) (V158)  | MSB11022 | 3 | 2.8–3.0                       | 2.9 (0.1)  | 0.2 0.4 0.6 0.8 1 1.2             |
|                      | Humira\(^a\) | 20 | 2.5–4.4 (2.5–3.4, 2.7–4.4)   | 3.1 (0.5)  | 0.2 0.4 0.6 0.8 1 1.2             |
| \(K_d\) (nM) (F158) | MSB11022 | 3 | 7.5–8.1                       | 8.0 (0.9)  | 0.2 0.4 0.6 0.8 1 1.2             |
|                      | Humira\(^a\) | 23 | 5.8–7.9 (5.8–7.9, 6.3–7.9)   | 6.9 (0.6)  | 0.2 0.4 0.6 0.8 1 1.2             |
| **Affinity to FcyRIIb by SPR** | | | | | |
| \(K_d\) (nM)           | MSB11022 | 3 | 5.6–7.8                       | 6.4 (1.1)  | 0.2 0.4 0.6 0.8 1 1.2             |
|                       | Humira\(^a\) | 13 | 5.2–9.8 (5.2–7.9, 5.6–9.8)   | 7.2 (1.5)  | 0.2 0.4 0.6 0.8 1 1.2             |
| **Affinity to Neonatal FcR by SPR** | | | | | |
| \(K_d\) (nM)           | MSB11022 | 3 | 61–67                         | 64.5 (3.4) | 0.2 0.4 0.6 0.8 1 1.2             |
|                       | Humira\(^a\) | 17 | 58–83 (58–93, 59–92)         | 76.9 (9.8) | 0.2 0.4 0.6 0.8 1 1.2             |
| **Relative Binding to C1q by ELISA** | | | | | |
| EC\(_{50}\) (%)         | MSB11022 | 3 | 100–114                       | 106.7 (7.0) | 0.2 0.4 0.6 0.8 1 1.2             |
|                       | Humira\(^a\) | 19 | 85–116 (88–114, 85–116)      | 100.9 (9.1) | 0.2 0.4 0.6 0.8 1 1.2             |

Abbreviations: EC50 = half-maximal effective concentration; ELISA = enzymelinked immunosorbent assay; Fab = fragment antigen-binding; Fc = fragment crystalizable; FcR = Fc receptor; KD = dissociation constant, N = number; SD = standard deviation; SPR = surface plasmon resonance; tm-TNF = transmembrane TNF; TNF = tumor necrosis factor. \(^a\)US and EU batches of Humira\(^a\). \(^b\)Bar diagrams represent MSB11022 max range normalized to Humira\(^a\) min/max range for each quality attribute. \(^c\)Labelled according to immunoGenetics (IMGT) numbering. \(^d\)Labelled according to EU numbering.

In-depth assessment of MSB11022 and Humira\(^a\) with state-of-the-art methods demonstrated high physicochemical and functional comparability between these 2 products. Our data also showed a similar or potentially greater variability among the different batches of Humira\(^a\) than between Humira\(^a\) and MSB11022 batches. This high variability among Humira\(^a\) batches may be surprising, but could be attributable to changes in the manufacturing process. This level of variability has also been observed for other originator biologics. In a study examining the comparability of rituximab (MabThera\(^a\)/Rituxan\(^a\); a mAb targeting the protein CD20) and a biosimilar rituximab, certain quality attributes shifted among batches of the originator. Product quality shifts have also been noted for Humira\(^a\). Up until 2013, 21 changes in the manufacturing process of the drug had been made. Nevertheless, it remains unclear what acceptable variations in batches for marketed biologics are.
In certain cases reported in Table 2, for example with regard to C-terminal amidated Pro, a minor population representing <5% of the mAb species in Humira® and 0.2% in MSB11022 was observed. Therefore, variability normalized to Humira® min–max ranges might be exacerbated by low levels of variants. The same might be true for truncated HC Delta (C-term GK), LMW species by SEC, aggregates/HMW species by AUC, and oxidation levels. Humira® also shows a larger range than MSB11022, with a similar mean, for glycated LC and HC and aggregates by SEC. It is worth highlighting that potential effects of drug age at the time of testing are unlikely to affect the relative comparison of MSB11022 and Humira®/C210, as all MSB11022 samples were tested at mid-shelf life. It should be noted that this Humira®/C210 intra-batch variability could also be attributed to the greater number of Humira® batches in this analysis.

Based on these findings, MSB11022 is anticipated to show pharmacokinetics, potency, safety, and efficacy comparable to those of Humira®.

Materials and methods

Materials

MSB11022 batches were manufactured on a large scale at the Merck Aubonne-Vevey site (Switzerland). In total, up to 23 batches of Humira® from various origins (EU, US) were analyzed to build a target quality range for MSB11022. The analytical similarity study presented here included 3 MSB11022 drug product batches, at least 3 Humira® drug product batches sourced from the EU, and at least 3 Humira® drug product batches sourced from the US. An MSB11022 internal reference standard (IRS 2013/01) obtained from a representative engineering run of MSB11022 drug substance was used as reference standard throughout the analytical similarity study.

The tested quality attributes obtained with either qualified or fully ICH Q2 (R1) validated methods are summarized in Table 1. Three US-licensed and 3 EU-approved Humira® batches were analyzed head-to-head against 3 MSB11022 batches, and up to 16 additional batches of Humira® were analyzed in different analytical sessions. Some analytical methods such as CD, Nano DSC, and AUC did not allow a head-to-head analysis. In such cases, batches of Humira® were tested in the same analytical session with MSB11022 batches in the presence of an internal reference standard, if needed.

Peptide mapping

The complete primary structure and posttranslational modifications including deamidation and oxidation and occupancy of the glycosylation site; Asn297 (HC) of MSB11022 and Humira® were assessed by peptide mapping by UPLC-MS/MS (numbering as per IMGT [the international ImMunoGeneTics information system®] nomenclature for variable domain regions and as per EU nomenclature for constant domain regions). First, disulfide bridges were reduced in the presence of 12.5 mM dithiothreitol (DTT) and 4 M guanidine-HCl in a tris(hydroxymethyl)aminomethane (Tris) buffer at pH 7.6 at 37°C for 1 hour. Then, alkylation of the tested drugs was performed in the dark in the presence of 29 mM iodoacetamide for 1 hour. The buffer was exchanged for 6 M urea and Tris buffer at pH 8.0. Prior to hydrolysis, the buffer was diluted 3-fold with Tris buffer pH 8.0. The digestion of MSB11022 and Humira® (0.5 mg) by trypsin (24 μg) provided specific peptides that were subsequently separated by UPLC using a C18 column (Acquity UPLC BEH, 1.7 μm, 2.1 μm × 100 mm; Waters) and acetonitrile gradient containing formic acid at a flow rate of 0.2 mL/min at 60°C. Absorbance was monitored at 214 nm. The separated peptides were further identified by a coupled online quadrupole time of flight (Q-TOF) mass spectrometer.

The primary structure of the tested proteins was compared with a list of theoretical tryptic digest peptides using BiopharmaLynx 1.3 software.

Identification of disulfide bridges (cysteine pairing) was performed in similar conditions, except that MSB11022 and Humira® were alkylated by maleimide and iodoacetamide, and digested by trypsin without a reduction step.
Whole-domain LC-MS

The whole-molecule analyses were performed by LC-MS by using a Q-TOF mass spectrometer. Samples were analyzed after N-glycanase treatment. Disulfide bridge reduction was performed prior to LC-MS analysis to reduce the complexity of the molecule and to separate the HC from the LC.

Figure 6. Comparison of FcγRlla binding by SPR between MSB11022 and Humira®. Representative surface plasmon resonance (SPR) sensorgrams of MSB11022 (batches AL1D001 [A], AL1D002 [B], AL1D003 [C]), Humira® US (batches 1004012 [D], 1017235 [E]), and EU (batch 37461XD07) binding to FcγRIIIa V158 and F158. The calculated curves are colored gray. The initial concentration of 50 nM (orange curve) was followed by 4 2-fold serial dilutions (other colored curves).
**Circular dichroism**

CD spectra were measured in the far-UV (190–260 nm) and the near-UV (250–340 nm) spectral regions with 0.3 mg/mL and 5 mg/mL of the tested drugs (diluted in deionized water; Millipore), respectively. Spectra were recorded with a JASCO spectropolarimeter (Japan Spectroscopic Co., model J-810) in a quartz cuvette (1-mm cell length; Hellma) at 20°C. Four scans were accumulated for each spectral region with a scan rate of 20 nm/min and 4-s response time. The data pitch and the bandwidth were 0.2 nm and 1 nm, respectively. For each measurement, the sample concentration was normalized by the absorbance measured at 280 nm for the near-UV and 215 nm in the far-UV regions. Spectra with deionized water were used for baseline correction. When baseline drifts occurred, spectra were corrected using a narrow interval in which the signal was practically zero compared with the main spectral features (far UV, 250–260 nm; near UV, 330–340 nm).

**Nano DSC**

MSB11022 and Humira® samples (0.5 mg/mL in deionized water; Millipore) were analyzed by nanometer-range differential scanning nanocalorimetry using Nano DSC Autosampler (TA Instruments model 602001). After 10 minutes of equilibration at 10°C, the thermograms were obtained with a scan rate of 1°C/min and for the range 40°C–100°C. After baseline correction, thermograms normalized to protein concentration were analyzed with NanoAnalyze Data Analysis (version 3.1.2 by TA Instruments) by mathematical deconvolution using a polynomial baseline model that defined the 3 Tms of the tested drugs.

**Bioanalyzer**

The purity of MSB11022 and Humira® samples (0.1 mg/mL) was analyzed using an automated ‘gel-on-a-chip’ electrophoretic method (Agilent 2100 Bioanalyzer and Agilent Protein 230 Kit [catalog number 5067-1518]). This method separates analytes based on differences in MW, allowing the identification of degradation products and impurities. Samples are loaded after 5 min incubation at 70°C in the presence of sodium dodecyl sulfate (SDS) and maleimide under either non-reducing (without DTT) or reducing conditions (with DTT). The detection was performed by fluorescence (excitation at 458–482 nm [max. 470 nm], detection at 510–540 nm [max. 525 nm]). Markers of 4.5 kDa and 240 kDa were used to calibrate the electropherograms.

**SEC-HPLC**

SEC-HPLC was performed under non-denaturing conditions with Alliance 2695 (Waters) HPLC system using a TSKgel SuperSW3000 column (internal diameter [ID] 4.6 mm, Tosoh) at a flow rate of 0.35 mL/min in sodium phosphate/perchlorate buffer at pH 6.3. The isocratic elution profile was monitored using UV absorbance at 214 nm.

**AUC**

Monomeric purity and the level of purity of HMW and LMW species were evaluated by AUC in sedimentation velocity experiments using Optima XL-I ultracentrifuge (Beckman Coulter) and MSB11022 and Humira® at 0.5 mg/mL. Sedimentation was performed at 40,000 rpm with 70 scans taken at 8-min intervals at 20°C using An-50Ti analytical rotor. The path length was 12 mm and analytes were detected at 280 nm. Data were assessed using the SEDFIT program to obtain the c(s) profile of sedimentation coefficient (s) values. A diffusion coefficient was assigned to each value based on the assumption that all species have the same overall hydrodynamic shape and using a frictional coefficient ratio relative to that of a sphere (f/f0) fitted to the data. The partial specific volume used for adalimumab was 0.73 mL/g.

**Charge variants by icIEF**

Isoform profile and abundance were characterized in MSB11022 and Humira® samples by icIEF. Samples included MSB11022 or Humira® (1.0 mg/mL), carrier ampholytes (Pharmalyte 5–8 and 8–10.5), methylcellulose, and internal PI markers (pI 7.05 and 9.50; Master mix solution, ProteinSimple). Electrophoresis was performed on icIEF capillary cartridge FC-coated (ID 100 μm × 50 mm, ProteinSimple) in a pH gradient created by the carrier ampholytes under the influence of an electric field (pre-focusing 1 min at 1500 V, focusing 6 min at 3000 V). Analytes were detected by absorbance at 280 nm.

**In vitro bioassay**

Biological activity of MSB11022 and Humira® was measured in a murine fibroblast L929-A9 cell line (A9 cell line derived from the L929 cell line) by evaluating the inhibition of cytotoxicity induced by a fixed concentration of TNF in the presence of cycloheximide as described previously. L929-A9 cells were loaded into a 96-well plate. MSB11022 or Humira® was then added together with cycloheximide (Sigma) and TNF (R&D). After an incubation of 24 h at 37°C, 5% CO2, viable cells were measured by “ATPlite 1 step” luminescence assay (Perkin Elmer); an ATP monitoring system based on Firefly luciferase. The count-per-second values (y-axis) were plotted versus each own Log_{10} transformed MSB11022 or Humira® concentration (x-axis) and fit by using a 4-parameter logistic (4PL) algorithm (GraphPad Prism). For each data set, the concentration of MSB11022 or Humira® able to inhibit TNF cytotoxicity at EC_{50} was automatically calculated. The relative potency was expressed as percentage of activity of drug test preparation with respect to IRS 2013/01. The relative potency of MSB11022 and Humira® for the neutralization of TNF cytotoxic activity was calculated as the mean of 3 independent experiments. The variability of this validated method was evaluated for both repeatability (intra-session) and intermediate precision, which showed 17% and 9% coefficients of variation, respectively.

**Surface plasmon resonance**

Binding of soluble TNF to MSB11022 or Humira® was monitored by real-time biomolecular interaction analysis based on the SPR approach. The kinetics and affinity were measured using Fc...
capture Biacore method and a T200 Biacore (GE Healthcare) instrument as described previously. Interactions of the analyte in solution (TNF) with the ligand (MSB11022 or Humira®) captured beforehand by the Fc portion on Protein A covalently linked on the CM5 sensor chip were monitored. Kinetics rate constants and affinity were determined using the 1:1 fitting model.

Affinity to FcγR proteins was measured after covalent binding of FcγR extracellular domain proteins (FcγRI, R&D; FcγRIIα, Novus and Merck Serono; FcγRIIIα, Novus; FcγRIIIα, R&D and Merck Serono; FcγRIIB, R&D) to a CM5 sensor chip surface by amine coupling. Based on literature findings showing quantifiable detection of anti-TNF antibody binding to low-affinity Fcγ receptors only in the presence of soluble TNF, MSB11022 or Humira® was complexed with TNF homotrimer (2:1 molar ratio) for interaction studies with FcγRIIα/b, and IIIa/b. Serial dilutions of TNF-bound MSB11022/Humira® or MSB11022/Humira® alone (FcγRI) were injected sequentially. For FcγRI (Merck Serono), the protein is covalently bound to a CM4 sensor chip surface by amine coupling. Serial dilutions of MSB11022 or Humira® alone at pH 6 were injected sequentially. Kinetics and affinity sensorsgrams were analyzed with a 2-state reaction-fitting model using Biacore Evaluation software. The Fab and Fc affinities of MSB11022 and Humira® were expressed as average of results measured from 2 to 3 independent experiments.

**FACS**

Binding of MSB11022 and Humira® to tm-TNF was measured. A dose-response curve of adalimumab was applied on tm-TNF expressing cells using flow cytometry. HEK293 recombinant cells (Merck Serono) overexpressing non-cleavable tm-TNF variant27 at their surface were incubated with serial dilutions of adalimumab and then stained with 5 μg/mL secondary PE-labeled goat anti-human IgG1 Fc-specific polyclonal antibody (Jackson). The specificity of tm-TNF binding was verified with human IgG1 isotype control (Sigma). After washing, the cells were analyzed on a flow cytometer (BD FACS Calibur). The background autofluorescence was subtracted from the mean fluorescence intensity of each peak determined with the CellQuest Pro Software (BD). The intensity of the fluorescent signal is directly proportional to the amount of adalimumab bound to tm-TNF on cells. Dose-response curves were evaluated using 4PL algorithm. The relative potency was expressed as EC50 of drug test preparation with respect to IRS 2013/01. The tm-TNF binding activity was calculated as the mean of 3 independent experiments.

**ELISA**

MSB11022 and or Humira® binding capability to the human C1q was determined by the ELISA. Different concentrations of adalimumab were coated onto a 96-well plate. Unbound sites were blocked with 1% bovine serum albumin, then a fixed concentration of C1q (2 μg/mL, Sigma) was added and incubated for 2 hours at room temperature. The reaction was completed by the addition of anti-C1q-HRP antibody conjugate (1:2000 Abcam) and a substrate (TMB Sigma) that generated a colorimetric reaction. The intensity of the colorimetric signal read at 450 nm is directly proportional to the C1q protein bound to the coated antibody. The experimental data were interpolated with the 4PL algorithm. The relative potency was expressed as mean relative EC50 of drug test preparation with respect to IRS 2013/01. The C1q binding activity was calculated as the mean of 3 independent assays.

**Disclosure of potential conflicts of interest**

This study was supported by Merck and Merck Biosimilars. The authors are employees of Merck and Merck Biosimilars. No other potential conflicts of interest were reported.

**Acknowledgments**

We thank colleagues at Merck and Merck Biosimilars who supported the work. We would like to thank Fabio Camerini, Sabrina Fiumi, Fabio Valensisi, Cristian Ferrao, Luisa Iozzino, Anna Izzo, Gabriella Leo, Erika Birolò, Abhijeet Satwekar, Ombretta Caruso, Alessia Pellegrini, Elisabetta Zannoni, Gabriella Angiuloni, and Francesca Cutillo for supporting physicochemical analysis; Francesca Cavaliere, Angela Pelliccia, Giordana Bruni, Anna Rita Pezziotti, Michele Mascia, Laure Bonnet, and Aurore Glez for supporting functional analysis; and Robert Schnepf from Merck Global Manufacturing & Supply and Fabrice Romanet, Michael Muenzberg, Georg Schmies, and Georg Feger for critical reading of the manuscript. Editorial support during the preparation of the manuscript was provided by Guillaume Schoch of Fishawack Archimied AG, part of the Fishawack Group of Companies, supported by Merck.

**References**

1. U.S. Food and Drug Administration. FDA is a biological product? [accessed 2016 Dec 21] http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194516.html
2. Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, Bae JS, Kim DI, Lee SY, Chang SJ. Physicochemical characterization of Remsima. mAbs 2014;6:1163-1173; PMID:25517302; http://dx.doi.org/10.4161/mabs.32221
3. Weise M, Bielsky MC, De Smet K, Ehmam F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonem E, Ho K, et al. Biosimilars: what clinicians should know. Blood 2012;120:5111-5117; PMID:23093622; http://dx.doi.org/10.1182/blood-2012-04-425744
4. Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol 2012; 7:S57-S67; PMID:22249658; http://dx.doi.org/10.1007/s12325-011-0196-3
5. McCamish M, Woollett G. Worldwide experience with biosimilar development. Mabs 2011;3:209-217; PMID:21441787; http://dx.doi.org/10.4161/mabs.3.2.15005
6. Jha A, Upton A, Dunlop WC, Akehurst R. The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries. Adv Ther 2015;32:742-756; PMID:26343027; http://dx.doi.org/10.1007/s12325-015-0231-1
7. Weise M, Kurki P, Wolf-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood 2014;124:3191-3196; PMID:25298038; http://dx.doi.org/10.1182/blood-2014-06-583617
8. AbbVie Inc. HUMIRA (adalimumab) injection, for subcutaneous use. 2016 Oct. [accessed 2016 Dec 21] http://www.rxabbvie.com/pdf/humira.pdf
9. AbbVie Inc. SPC Humira 40 mg/0.4 ml Pre-filled Syringe and Pre-filled Pen. 2016 Sep 23. [accessed 2016 Dec 21] https://www.medicines.org.uk/emc/medicine/21201
10. EMA. Summary of opinion (post authorisation): Humira (adalimumab). 2016 May 26. [accessed 2016 Dec 21] http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000481/WC500207152.pdf
11. Wen D, Vecchi MM, Gu S, Su L, Dolnikova J, Huang YM, Foley SF, Garber E, Pederson N, Meier W. Discovery and investigation of misincorporation of serine at asparagine positions in recombinant proteins expressed in Chinese hamster ovary cells. J Biol Chem 2009;284:32686-32694; PMID:19783658; http://dx.doi.org/10.1074/jbc.M109.059360
12. Ionescu RM, Vlasak J, Price C, Kirchmeier M. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 2008;97:1414-1426; PMID:17721938; http://dx.doi.org/10.1002/jps.21104

13. Garber E, Demarest SJ. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun 2007;355:751-757; PMID:17321501; http://dx.doi.org/10.1016/j.bbrc.2007.02.042

14. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for Industry. [accessed 2016 Dec 21] http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf

15. Brorson K, Kendrick B. Perspectives on well-characterized biological proteins. In: Schiel JE, Davis DL, Borisov OV, editors. State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization. Vol. 1. Monoclonal anti-body therapeutics: structure, function, and regulatory space. Washington, DC: ACS; 2014. p. 99-116; doi:10.1021/bk-2014-1176.ch004

16. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29:310-312; PMID:21478841; http://dx.doi.org/10.1038/nbt.1839

17. Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, Preksaritanont T, Ionescu R. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 2011;48:860-866; PMID:21256596; http://dx.doi.org/10.1016/j.molimm.2010.12.009

18. Bertolotti-Ciarlet A, Wang W, Lownesa R, Pristatsky P, Fang Y, McKelvey T, Li Y, Li Y, Drummond J, Prueksarita T, et al. Impact of methionine oxidation on the binding of human IgG1 Fc to FcRn and Fcγ receptors. Mol Immunol 2009;46:1878-1882; PMID:19269032; http://dx.doi.org/10.1016/j.molimm.2009.02.002

19. Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgGs engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281(33):23514-23524. Epub 2006 Jun 21; PMID:16793771; http://dx.doi.org/10.1074/jbc.M604292200

20. Robbie GJ, Criste R, Dall’acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 2013; 57(12):6147-6153; PMID:24080653; http://dx.doi.org/10.1128/AAC.01285-13

21. Hyland E, Mant T, Vlachos P, Attkins N, Ullmann M, Roy S, Wagner V. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects. Br J Clin Pharmacol 2016;82:983-993; PMID:27285856; http://dx.doi.org/10.1111/bcp.13039

22. Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 2013; 27(5):495-507; PMID:23649935; http://dx.doi.org/10.1007/s40259-013-0036-3

23. Tebbey PW, Varga A, Naill M, Clewell J, Venema J. Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab). mAbs 2015;7(5):805-811; PMID:26230301; http://dx.doi.org/10.1080/19420862.2015.1073429

24. Terlizzese M, Simonpi E, Antonetti F. In vitro comparison of inhibiting ability of soluble TNF receptor p75 (TBP II) vs. soluble TNF receptor p55 (TBP I) against TNF-alpha and TNF-beta. J Interferon Cytokine Res 1996; 16:1047-1053; PMID:8974008; http://dx.doi.org/10.1089/jir.1996.16.1047

25. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzagat DK, Salefield J, Sasso EH. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131:308-316; PMID:19188093; http://dx.doi.org/10.1016/j.clim.2009.01.002

26. Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohono T. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009; 45:124-31; PMID:19128982; http://dx.doi.org/10.1016/j.cyto.2008.11.008

27. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Gorgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83:793-802; PMID:8521496; http://dx.doi.org/10.1016/0092-8674(95)90192-2

28. ICH harmonised tripartite guideline. Validation of analytical procedures: text and methodology Q2(R1). Current Step 4 version. 2005 Nov. [accessed 2016 Dec 21] http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1_Guideline.pdf